Recruiting

Observational Study

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT01212003

Conditions

Mycobacterium Infections

Tuberculosis, Multidrug-Resistant

Latent Tuberculosis

Tuberculosis

Extensively Drug-Resistant Tuberculosis

Eligibility Criteria

Sex: All

Age: 2 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Background:

\- Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for research and treatment studies.

Objectives:

\- To collect blood and other samples to study the natural history of tuberculosis.

Eligibility:

\- Individuals 2 years of age and older who have either active or latent tuberculosis.

Design:

  • Latent TB patients: Participants will have a single study visit with a physical examination and medical history, and will provide blood samples for testing.
  • Active TB patients: Participants will have an initial visit with a physical examination and medical history, and will provide blood samples for testing. Participants will also provide sputum samples if required, and may have an optional skin punch biopsy to collect a sample of skin tissue for study.
  • Treatment for active TB will be provided as part of this protocol.
  • Active TB participants may be asked to return for study visits every 1-2 months while receiving treatment....

Conditions

Mycobacterium Infections

Tuberculosis, Multidrug-Resistant

Latent Tuberculosis

Tuberculosis

Extensively Drug-Resistant Tuberculosis

Study ID

NCT01212003

Start date

Jun 30, 2011

Status verified date

Jan 27, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2 - 70+

Healthy Volunteers: Not accepted

  • INCLUSION CRITERIA:

FOR ALL PATIENTS

Patients may be included in this study who:

  • Have or are suspected to have TB infection.
  • Are aged 2 years or older.
  • Have a primary care physician, infectious diseases physician, pulmonologist, or TB specialist outside of the NIH who can provide care of his or her TB infection outside the NIH, provide directly observed therapy (DOT) if necessary, and monitor for side effects and toxicity of TB medications.
  • Are willing to consent to storage of specimens for future research.
  • Able to provide informed consent for themselves or, if they lack the capacity to provide informed consent, have an appropriate Legally Authorized Representative (LAR; the study team will comply with NIH Human Research Protection Program \[HRPP\] Policy 403).

FOR PATIENTS WITH LATENT TB

In addition to the above-described inclusion criteria for all patients, patients may be included in the Latent TB part of this protocol who:

-Have documented evidence of a positive purified protein derivative (PPD) skin test or Interferon-gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB; conversion can have occurred at any time.

FOR PATIENTS WITH ACTIVE TB

In addition to the above-described inclusion criteria for all patients, patients may be included in the Active TB part of this protocol who:

  • Have active TB of any drug susceptibility pattern and any site of infection as determined by smear, culture, or biopsy.
  • Have appropriately documented clinically suspicious active TB without definitive microbiology confirmation.

EXCLUSION CRITERIA:

Patients will be excluded from this study who:

  • Are incarcerated.
  • Have been ordered by a court to take TB medications.
  • Are unwilling or unable to comply with prescribed therapy.
  • Are pregnant.

EXCLUSION OF SPECIFIC POPULATIONS

Children: Children under the age of 2 are not eligible to enroll. The addition of the very young will not provide enough additional insights to justify the risk to this specific population.

Pregnant women: Pregnant women are not eligible for participation in this protocol because the study objectives can be achieved without the enrollment of this population. Enrolled participants who become pregnant during the study will be withdrawn.

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Arms

Active TB

subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation

Latent TB

subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB

Primary outcome measure

  • Increase in the number of TB patients being actively followed at the NIH CC to provide information on TB patients with DS and drug-resistant disease for hypothesis generation and hands-on experience in the management of TB [ Time Frame: ongoing ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

More Information

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last update posted

Sep 1, 2026

Last verified

Jan 27, 2026

Keywords

  • TB
  • Mycobacterium Tuberculosis
  • Active Tuberculosis
  • Latent Tuberculosis
  • MDR TB
  • Natural History
  • Tuberculosis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-09-01.